中金发表报告指,再鼎医药(09688.HK) (ZLAB.US) 首季收入9,960万美元,按年下降6%;净亏损5,100万美元,业绩符合预期。该行指,Zoci正处于全球注册性临床III期阶段,关注数据读出及管线进展。公司另有多个潜在重磅管线进入临床阶段。据公司公告,ZL1503(IL-13/IL-31Rα)正在全球1/1b期入组中,公司预计下半年首次人体数据读出,建议关注PK/PD/...
Source Link中金发表报告指,再鼎医药(09688.HK) (ZLAB.US) 首季收入9,960万美元,按年下降6%;净亏损5,100万美元,业绩符合预期。该行指,Zoci正处于全球注册性临床III期阶段,关注数据读出及管线进展。公司另有多个潜在重磅管线进入临床阶段。据公司公告,ZL1503(IL-13/IL-31Rα)正在全球1/1b期入组中,公司预计下半年首次人体数据读出,建议关注PK/PD/...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.